With more patients receiving immune-modularity therapies (e.g., high dose corticosteroids or anti-TNF therapy) for autoimmune and inflammatory conditions and improvements in the recognition of primary immune deficiencies, the at-risk population continues to expand, with PcP being diagnosed in patients considered, typically, at lower risk (Table 1) [8,9]. This evidence concerns the gene TNF and pneumocystosis.